Ultragenyx Pharmaceutical reported $0 in Debt for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Debt Change
Alnylam Pharmaceuticals ALNY:US USD 1.02B 967K
Aptinyx Inc APTX:US USD 24.71M 211K
Biocryst Pharmaceuticals BCRX:US USD 733.28M 19.63M
Biomarin Pharmaceutical BMRN:US USD 1.09B 3.46M
Esperion Therapeutics ESPR:US USD 259.9M 412K
Insmed INSM:US USD 1.16B 348.29M
Karyopharm Therapeutics KPTI:US USD 302.82M 69K
Kyowa Hakko Kirin 4151:JP JPY 23.28B 1.16B
Moderna Inc MRNA:US USD 1.07B 73M
Neurocrine Biosciences NBIX:US USD 169.4M 200K
Ptc Therapeutics PTCT:US USD 1.35B 289.13M
Puma Biotechnology PBYI:US USD 98.31M 313K
Regeneron Pharmaceuticals REGN:US USD 2.7B 300K
Sarepta Therapeutics SRPT:US USD 1.54B 1.52M
Vertex Pharmaceuticals VRTX:US USD 471.6M 29.3M